China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
TSMC Posts Record Q1 2026 Profits Driven by Surging AI Chip Demand 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
WALTHAM, Mass., June 07, 2017 -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation at the Goldman Sachs 38th Annual Global Healthcare Conference, to be held June 13-15, 2017 at the Terranea Resort in Rancho Palos Verdes, California. Tim Pearson, EVP and CFO of TESARO, will present at 10:40 AM PT on June 15 and will participate in meetings with investors.
A live webcast of the presentation will be available by visiting the Investors section of the TESARO website at www.tesarobio.com. An archived replay of this webcast will be available on the Company’s website for 14 days following the conferences.
About TESARO
TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.
For additional information, please contact: Jennifer Davis 1.781.325.1116 [email protected]
